AIM ImmunoTech

AIM ImmunoTech Retained Earnings

The Retained Earnings of AIM ImmunoTech (AIM) as of Nov 20, 2026 is -440.79 M USD. In the previous year, Retained Earnings was -426.83 M USD — a change of 3.27% (lower).

Retained Earnings

-440.79 MUSD

YoY

3.27%

Last updated:

Retained Earnings of AIM ImmunoTech is 2025 -440.79 M USD. Retained Earnings of AIM ImmunoTech was 2024 -426.83 M USD. It decreases by 3.27% lower compared to the previous year.

The AIM ImmunoTech Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-318.57 M USD
Jan 1, 2019
-328.11 M USD
Jan 1, 2020
-341.97 M USD
Jan 1, 2021
-361.10 M USD
Jan 1, 2022
-380.55 M USD
Jan 1, 2023
-409.51 M USD
Jan 1, 2024
-426.83 M USD
Jan 1, 2025
-440.79 M USD
The AIM ImmunoTech Retained Earnings history
YEARRetained EarningsYoY
-440.79 MUSD+3.27%
-426.83 MUSD+4.23%
-409.51 MUSD+7.61%
-380.55 MUSD+5.38%
-361.10 MUSD+5.59%
-341.97 MUSD+4.23%
-328.11 MUSD+2.99%
-318.57 MUSD+3.18%
-308.76 MUSD+2.75%
-300.50 MUSD+2.56%
-293.00 MUSD+5.48%
-277.77 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AIM ImmunoTech Stock analysis

What does AIM ImmunoTech do? AIM ImmunoTech, Inc. generates revenue primarily through the sales and marketing of Alferon N Injection, an approved treatment for refractory or recurring external genital warts in patients over 18. The company also develops Ampligen, a drug in clinical development for Chronic Fatigue Syndrome, and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon. Its primary customer segments include patients with viral and immune-based chronic disorders requiring specialized therapies. The firm's R&D segment focuses on Ampligen and other drugs under development, while its commercial segment handles Alferon product sales. Alferon N Injection is marketed for intralesional treatment of genital warts, targeting healthcare providers who prescribe it to adult patients. Ampligen is positioned for clinical trials in Chronic Fatigue Syndrome, with potential future commercialization. Alferon LDO represents a novel oral delivery method for natural interferon, targeting patients seeking non-invasive treatment options. The company's revenue streams are derived from both current product sales and future potential drug development milestones. The firm's business model centers on leveraging natural immune system enhancing technologies to address unmet medical needs in viral and immune-based disorders. Its products are developed through clinical trials and regulatory approvals, with Alferon N Injection already approved for specific indications. The company's focus on R&D and commercialization of these therapies defines its market position within the biopharmaceutical sector. AIM ImmunoTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AIM ImmunoTech stock

Retained Earnings of AIM ImmunoTech is -440.79 M USD in 2025.

Retained Earnings of AIM ImmunoTech changed from -426.83 M USD to -440.79 M USD, representing a 3.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings AIM ImmunoTech since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's AIM ImmunoTech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AIM ImmunoTech

All Key Metrics — AIM ImmunoTech